- Report
- August 2024
- 150 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- October 2024
- 200 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- January 2025
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- March 2021
- 149 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- April 2023
- 96 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- November 2023
- 215 Pages
China
From €3818EUR$4,000USD£3,199GBP
- Report
- November 2023
- 109 Pages
China
From €1718EUR$1,800USD£1,439GBP
- Report
- February 2021
- 225 Pages
Global
From €3298EUR$3,456USD£2,764GBP
Telmisartan is a drug used to treat high blood pressure and reduce the risk of cardiovascular disease. It belongs to a class of drugs known as angiotensin receptor blockers (ARBs). Telmisartan works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow, leading to an increase in blood pressure. It also helps to reduce the risk of stroke, heart attack, and other cardiovascular events. Telmisartan is usually taken once a day, with or without food. It is available in tablet form and is usually taken with other medications to treat high blood pressure.
Telmisartan is a widely used drug in the cardiovascular market. It is used to treat hypertension, reduce the risk of stroke and heart attack, and improve overall cardiovascular health. It is also used to reduce the risk of developing type 2 diabetes.
Companies in the Telmisartan market include Pfizer, Novartis, Merck, Sanofi, and AstraZeneca. Show Less Read more